120 completed, 13 unknown, 11 terminated, 8 withdrawn. 158 Phase 1, 46 Phase 2.
Follow Nose Diseases: new trials by email Literature Review of Nose Diseases trials Research Report on Nose Diseases
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Topical TOR-582 Treatment of Epistaxis in HHT Topical sirolimus ointment - Hereditary Hemorrhagic Telangiectasia (HHT), Epistaxis | Phase 1 | Not yet recruiting | Columbia University | 27 | 2027-03-01 | 2026-11-06 |
| Docetaxel and SX-682 in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma, Salivary Gland Carcinoma, and Advanced Prostate Cancer SX-682, DTX - Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma | Phase 1 / Phase 2 | Recruiting | National Cancer Institute (NCI) | 120 | 2026-11-11 | 2026-11-06 |
| Efficacy and Safety of Yiqi Wenyang Sanhan Formula Combined With Acupoint Application in Patients With Combined Allergic Rhinitis and Asthma Syndrome During Remission and Yang-Deficiency Syndrome Yiqi Wenyang Sanhan Formula Combined with Acupoint Application, placebo of Yiqi Wenyang Sanhan Formula combined with acupoint application - Allergic Rhinitis With Asthma | Phase 1 | Not yet recruiting | Beijing Daxing District Hospital of Integrated Chinese and Western Medicine | 188 | 2026-09-01 | 2026-04-20 |
| Phase 1, First in Human (FIH), Open-Label, Single-Arm, Ascending Dose Study to Assess the Safety, Tolerability and Preliminary Immunogenicity of ITI-9001 in Japanese Patients With Japanese Red Cedar (JRC) Pollinosis ITI-9001, Placebo - Allergen Immunotherapy | Phase 1 | Recruiting | Immunomic Therapeutics, Inc. | 45 | 2026-06-20 | 2026-09-25 |
| A Phase 1 Study of Cizutamig in IgE Mediated Diseases Cizutamig - IgE-Mediated Hypersensitivity, IgE Mediated Food Allergy | Phase 1 | Withdrawn | Candid Therapeutics | 2026-04-01 | 2026-07-22 | |
| A Trial of TER-1754 in Patients With Hereditary Hemorrhagic Telangiectasia TER-1754, Placebo - Hereditary Hemorrhagic Telangiectasia (HHT) | Phase 1 | Withdrawn | Terremoto Biosciences Inc. | 2025-12-15 | 2026-04-13 | |
| Bioequivalence Study of AJU-R713 and R713R in Healthy Adult Volunteers AJU-R713, R713R - Bronchial Asthma, Perennial Allergic Rhinitis | Phase 1 | Completed | AJU Pharm Co., Ltd. | 62 | 2025-12-12 | 2026-09-18 |
| Phase I Study of PollenVax in Patients With Mugwort Pollen-Induced Allergic Rhinitis PollenVax, Placebo - Rhinitis Allergic | Phase 1 | Completed | Kazakh National Agrarian University | 30 | 2025-11-22 | 2026-06-29 |
| Safety and Immunogenicity of Cat-allergen Intralymphatic Immunotherapy in Patients With Cat Allergy With and Without Asthma ALUTARD SQ® Felis domesticus - Allergic Rhinitis, Allergic Asthma | Phase 1 / Phase 2 | Recruiting | University of Zurich | 36 | 2025-08-20 | 2026-03-16 |
| Study on the Safety, Tolerability, and Pharmacokinetics of PA9159 Nasal Spray in Healthy Adult Subjects PA9159 nasal spray solution, 80 μg one day treatment, PA9159 nasal spray solution, 160 μg one day treatment, PA9159 nasal spray solution, 320 μg one day treatment - Allergic Rhinitis | Phase 1 | Completed | Anhui Palo Alto Pharmaceuticals, Inc. | 36 | 2025-03-14 | 2026-01-15 |
| Serum sST2/ miR-223 as a Dual Biomarker for Disease Activity & Clinical Efficacy of SLIT in HDM-Induced Allergic Rhinitis Sublingual Immunotherapy (SLIT) containing HDM extracts - HDM-Induced Allergic Rhinitis | Phase 1 | Completed | Zagazig University | 54 | 2025-02-01 | 2026-02-27 |
| A Study to Evaluate ALN-6400 in Healthy Volunteers and Patients With Hereditary Hemorrhagic Telangiectasia (HHT) ALN-6400, Placebo - Hereditary Hemorrhagic Telangiectasia | Phase 1 / Phase 2 | Active not recruiting | Alnylam Pharmaceuticals | 89 | 2024-11-07 | 2026-10-15 |
| A Clinical Trial for Evaluation of Efficacy, Safety and Immunogenicity of GNR-127 (Recombinant ABP Antigen Protein Which Carries a Birch Pollen Allergen [BET V 1] and an Apple Allergen [MAL D 1]) in Patients With Birch Pollen Allergic Rhinitis. GNR-127, 20 mcg, GNR-127, 40 mcg, GNR-127, 80 mcg - Rhinitis, Allergic, Seasonal | Phase 1 / Phase 2 | Completed | AO GENERIUM | 150 | 2024-10-07 | 2026-09-21 |
| Trial of INI-2004 in Healthy Volunteers and Participants With Allergic Rhinitis. INI-2004, Placebo - Allergic Rhinitis Due to Weed Pollen, Allergic Rhinitis | Phase 1 | Completed | Inimmune Corporation | 68 | 2023-07-04 | 2026-01-16 |
| Pazopanib for the Treatment of Epistaxis in Hereditary Hemorrhagic Telangiectasia Pazopanib - Hereditary Hemorrhagic Telangiectasia, Epistaxis | Phase 1 / Phase 2 | Unknown | Cure HHT | 30 | 2023-07-01 | 2022-09-08 |
| Study to Compare the Pharmacokinetics of Fixed-Dose Combination of Mometasone + Azelastine Nasal Spray to Mometasone and Azelastine Nasal Sprays in Adolescents and Young Adults With Seasonal Allergic Rhinitis Mometasone + Azelastine, Mometasone Furoate, Azelastine Hydrochloride - Seasonal Allergic Rhinitis | Phase 1 | Terminated | Sandoz | 38 | 2023-06-08 | 2023-09-28 |
| Nasal Irrigation With Combination of 0.9% NaCl and Binahong Extract (Anredera Cordifolia) 2,5% In Allergic Rhinitis extract Binahong, Isotonic saline nasal irrigation - Allergic Rhinitis, Allergic Rhinitis Due to House Dust Mite | Phase 1 | Unknown | Gadjah Mada University | 80 | 2023-05-06 | 2024-02-28 |
| Bioequivalence Study of Azelastine Hydrochloride/ Fluticasone Propionate 137 Microgram/50 Microgram Nasal Spray and Dymista Nasal Spray Azelastine Hydrochloride/ Fluticasone propionate nasal spray, 'DYMISTA' NASAL SPRAY - Seasonal Allergic Rhinitis, Perennial Allergic Rhinitis | Phase 1 | Completed | Humanis Saglık Anonim Sirketi | 56 | 2023-03-24 | 2023-12-28 |
| Mechanism of EGR2 in Allergic Rhinitis EGR2 - Rhinitis, Allergic | Phase 1 | Unknown | Zu-xia Ma | 3 | 2023-01-30 | 2023-02-13 |
| A Study of Genolair in Two Dosage Forms (Solution and Lyophilisate) and Xolair® in Healthy Volunteers Genolair, solution for subcutaneous administration, 150 mg, Genolair, lyophilisate for the preparation of solution for subcutaneous administration, Xolair®, solution for subcutaneous administration, 150 mg - Allergic Asthma | Phase 1 | Completed | AO GENERIUM | 180 | 2023-01-15 | 2024-07-10 |
Showing 20 of 158. Sign in to see all of them.
Rhinitis, Allergic (79) · Rhinitis, Allergic, Seasonal (35) · Asthma (21) · Hypersensitivity (17) · Rhinitis, Allergic, Perennial (15) · Rhinitis (14) · Sinusitis (8) · Epistaxis (7) · Nasal Obstruction (7) · Nasal Polyps (7) · Telangiectasia, Hereditary Hemorrhagic (7) · Rhinosinusitis (6) · Dermatitis, Atopic (5) · Dust Mite Allergy (5) · Conjunctivitis, Allergic (4)
Otorhinolaryngologic Diseases (157) · Respiratory Tract Diseases (156) · Hypersensitivity, Immediate (118) · Immune System Diseases (118) · Rhinitis (117) · Respiratory Hypersensitivity (116) · Hypersensitivity (102) · Rhinitis, Allergic (38) · Infections (32) · Respiratory Tract Infections (28) · Bronchial Diseases (22) · Lung Diseases (22) · Lung Diseases, Obstructive (22) · Pathological Conditions, Signs and Symptoms (19)
Fluticasone (6) · Sodium Chloride (5) · azelastine (5) · Oxymetazoline (4) · Saline Solution (4) · Mometasone Furoate (3) · Sublingual Immunotherapy (3) · montelukast (3) · AZD8848 (2) · Allergens (2) · Beclomethasone (2) · Budesonide (2) · Diphenhydramine (2) · Nasal Sprays (2) · Omalizumab (2)
GlaxoSmithKline (12) · National Institute of Allergy and Infectious Diseases (NIAID) (6) · Stallergenes Greer (5) · Pfizer (4) · Gachon University Gil Medical Center (3) · Johnson & Johnson Consumer and Personal Products Worldwide (3) · Novartis (3) · University of North Carolina, Chapel Hill (3) · AO GENERIUM (2) · Allergy Therapeutics (2) · Anergis (2) · Anhui Palo Alto Pharmaceuticals, Inc. (2) · AstraZeneca (2) · Faes Farma, S.A. (2) · Gilead Sciences (2)
United States (52) · Germany (11) · South Korea (11) · Canada (10) · United Kingdom (10) · Australia (6) · China (6) · Japan (5) · Sweden (4) · Switzerland (4) · Austria (3) · Egypt (3) · France (3) · Netherlands (3) · Denmark (2)
Robert Wood, MD (4) · Christine Kolb (2) · David Peden, MD (2) · Francois Spertini, MD (2) · Friedrich Horak, MD (2) · Oksana A. Markova, MD (2) · Peter Catalano, MD (2) · Sang Min Lee, M.D., Ph.D. (2) · Stephen J Pollard, MD (2) · Aditi Mehta, DO (1)
PMID 24184147, PMID 19001265, PMID 22464647, PMID 19680119, PMID 22726593, PMID 23374268, PMID 24035151, PMID 26706294, PMID 10831441, PMID 11069570, PMID 11297958, PMID 11468003, PMID 15125017, PMID 15379842, PMID 16553814, PMID 17083353, PMID 19559969, PMID 19647862, PMID 19717725, PMID 19794023, PMID 20921983, PMID 21246519, PMID 21271600, PMID 21642470, PMID 21725898, PMID 22393898, PMID 22469599, PMID 22621776, PMID 23181790, PMID 23255493, PMID 23725004, PMID 24105252, PMID 24261946, PMID 24439076, PMID 24934402, PMID 24986270, PMID 24990880, PMID 25137523, PMID 25149431, PMID 26044169, PMID 26342289, PMID 26452438, PMID 26553448, PMID 26843086, PMID 26915677, PMID 27231527, PMID 27253988, PMID 27357167, PMID 27536452, PMID 27677865
2009 (3), 2014 (1), 2023 (1), 2025 (1)